The second mini-transplant for unstable mixed chimerism within the first 100 days after hematopoietic stem cell transplant in severe thalassemia

Allogeneic HSCT is the only curative treatment for severe thalassemia disease. MC occurs in one-third of these patients within the first two months after HSCT; this is a major risk factor of graft rejection, especially when RHCs are more than 25%. There is still no consensus for the management of MC...

Full description

Saved in:
Bibliographic Details
Main Authors: Choeyprasert,W., Pakakasama,S., Anurathapan,U., Songdej,D., Sirachainun,N., Sirireung,S., Panthangkool,W., Hongeng,S.
Format: Article
Published: Wiley-Blackwell 2015
Subjects:
Online Access:http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84864621281&origin=inward
http://cmuir.cmu.ac.th/handle/6653943832/38221
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Chiang Mai University
id th-cmuir.6653943832-38221
record_format dspace
spelling th-cmuir.6653943832-382212015-06-16T07:46:38Z The second mini-transplant for unstable mixed chimerism within the first 100 days after hematopoietic stem cell transplant in severe thalassemia Choeyprasert,W. Pakakasama,S. Anurathapan,U. Songdej,D. Sirachainun,N. Sirireung,S. Panthangkool,W. Hongeng,S. Pediatrics, Perinatology and Child Health Transplantation Allogeneic HSCT is the only curative treatment for severe thalassemia disease. MC occurs in one-third of these patients within the first two months after HSCT; this is a major risk factor of graft rejection, especially when RHCs are more than 25%. There is still no consensus for the management of MC, especially in the early phase of HSCT. The DLI has also been described in the treatment of MC following HSCT for hemoglobinopathies, but its success is still not guaranteed. The second HSCT has been an approach used in an attempt to cure patients who reject their graft. Concern about toxicity of conditioning regimen, the second HSCT is usually delayed for at least a year after the first HSCT. We would like to demonstrate the successful use of the second mini-allogeneic HSCT in hemoglobin E/β-thalassemia with evidence of unstable MC in the first 100 days after allogeneic HSCT to prevent further graft loss after allogeneic HSCT. © 2011 John Wiley & Sons A/S. 2015-06-16T07:46:38Z 2015-06-16T07:46:38Z 2012-09-01 Article 13973142 2-s2.0-84864621281 10.1111/j.1399-3046.2011.01577.x 21895905 http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84864621281&origin=inward http://cmuir.cmu.ac.th/handle/6653943832/38221 Wiley-Blackwell
institution Chiang Mai University
building Chiang Mai University Library
country Thailand
collection CMU Intellectual Repository
topic Pediatrics, Perinatology and Child Health
Transplantation
spellingShingle Pediatrics, Perinatology and Child Health
Transplantation
Choeyprasert,W.
Pakakasama,S.
Anurathapan,U.
Songdej,D.
Sirachainun,N.
Sirireung,S.
Panthangkool,W.
Hongeng,S.
The second mini-transplant for unstable mixed chimerism within the first 100 days after hematopoietic stem cell transplant in severe thalassemia
description Allogeneic HSCT is the only curative treatment for severe thalassemia disease. MC occurs in one-third of these patients within the first two months after HSCT; this is a major risk factor of graft rejection, especially when RHCs are more than 25%. There is still no consensus for the management of MC, especially in the early phase of HSCT. The DLI has also been described in the treatment of MC following HSCT for hemoglobinopathies, but its success is still not guaranteed. The second HSCT has been an approach used in an attempt to cure patients who reject their graft. Concern about toxicity of conditioning regimen, the second HSCT is usually delayed for at least a year after the first HSCT. We would like to demonstrate the successful use of the second mini-allogeneic HSCT in hemoglobin E/β-thalassemia with evidence of unstable MC in the first 100 days after allogeneic HSCT to prevent further graft loss after allogeneic HSCT. © 2011 John Wiley & Sons A/S.
format Article
author Choeyprasert,W.
Pakakasama,S.
Anurathapan,U.
Songdej,D.
Sirachainun,N.
Sirireung,S.
Panthangkool,W.
Hongeng,S.
author_facet Choeyprasert,W.
Pakakasama,S.
Anurathapan,U.
Songdej,D.
Sirachainun,N.
Sirireung,S.
Panthangkool,W.
Hongeng,S.
author_sort Choeyprasert,W.
title The second mini-transplant for unstable mixed chimerism within the first 100 days after hematopoietic stem cell transplant in severe thalassemia
title_short The second mini-transplant for unstable mixed chimerism within the first 100 days after hematopoietic stem cell transplant in severe thalassemia
title_full The second mini-transplant for unstable mixed chimerism within the first 100 days after hematopoietic stem cell transplant in severe thalassemia
title_fullStr The second mini-transplant for unstable mixed chimerism within the first 100 days after hematopoietic stem cell transplant in severe thalassemia
title_full_unstemmed The second mini-transplant for unstable mixed chimerism within the first 100 days after hematopoietic stem cell transplant in severe thalassemia
title_sort second mini-transplant for unstable mixed chimerism within the first 100 days after hematopoietic stem cell transplant in severe thalassemia
publisher Wiley-Blackwell
publishDate 2015
url http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84864621281&origin=inward
http://cmuir.cmu.ac.th/handle/6653943832/38221
_version_ 1681421434173259776